|
|
|
|
| LEADER |
01509nam a2200313 u 4500 |
| 001 |
EB001897085 |
| 003 |
EBX01000000000000001060090 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200523 r ||| eng |
| 100 |
1 |
|
|a Williams, D.
|
| 245 |
0 |
0 |
|a Triple conventional synthetic disease-modifying anti-rheumatic drugs for the management of rheumatoid arthritis
|h Elektronische Ressource
|b a review of cost-effectiveness
|c D. Williams, R. Butcher
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c March 26, 2019, 2019
|
| 300 |
|
|
|a 1 PDF file (18 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Antirheumatic Agents / therapeutic use
|
| 653 |
|
|
|a Arthritis, Rheumatoid / drug therapy
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Meta-Analysis as Topic
|
| 653 |
|
|
|a Treatment Outcome
|
| 700 |
1 |
|
|a Butcher, Robyn
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK547073
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a The aim of this report is to summarize the cost-effectiveness evidence on triple csDMARDs therapy (specifically, methotrexate, sulfasalazine, hydroxychloroquine) relative to other pharmacologic options for the management of RA in North America
|